TapImmune Inc. (OTCBB: TPIV), Chairman and CEO is pleased to provide this corporate update to our shareholders and other interested parties.

TapImmune Inc. (OTCBB: TPIV) has signed a sub-lease for newly-renovated, state of the art laboratory and office space at 1551 Eastlake Avenue in South Lake Union -- in the heart of Seattle's vibran...

Former executive at ID Biomedical and Biomira Inc brings broad experience and expertise in Cancer and Biodefense product development

TapImmune Inc. (OTCBB: TPIV) is pleased to announce a collaboration with Nature Immunology and Arkitek Studios to visualize TAP's role in combating disease.

TapImmune Inc. (OTCBB: TPIV) announced that it has signed a Research Collaboration with Aeras. The overall goal of this collaboration will be to evaluate the efficacy of TAP in concert with novel v...

Patent with broad claims relates to Method of Enhancing an Immune Response by augmenting the levels of TAP

SEATTLE, WA TapImmune Inc. (OTCBB: TPIV), a biotechnology company developing immunotherapies, today announced that its Chairman and CEO, Dr. Glynn Wilson, is an invited speaker at BIT's 2nd Annual...

SEATTLE, WA & Rochester, Minn. TapImmune Inc. (OTCBB: TPIV), a leading biotechnology company developing immunotherapies, today announced that following FDA IND approval, it will sponsor a Phase I H...

TapImmune Inc. (OTCBB: TPIV), a biotechnology company specializing in the development of immunotherapeutics and vaccines in the areas of oncology and infectious disease...

TapImmune Inc. (OTCBB: TPIV), is pleased to provide this corporate update to our current and future shareholders and other interested parties.

The article (http://www.cpreports.com/?p=931), written by respected business writer Gene Marcial, provides insights into recent progress of TapImmune Inc. (OTCBB:TPIV), its research and development...

TapImmune Inc. (OTCBB: TPIV), wishes to provide a clarification to the Press Release issued on March 1, 2011 ‘TapImmune Closes $1.16 Million Funding’

TapImmune Inc. (OTCBB: TPIV), is pleased to announce the closing of a $1.16M funding.

TapImmune Inc. (OTCBB:TPIV - News). Over the last 12 months we have made significant progress in moving TapImmune and its technology platform toward the clinic.

TapImmune Inc. (OTCBB: TPIV), is pleased to announce the following appointment to its Board of Directors:

TapImmune Inc. (OTCBB: TPIV) announced that it has signed a Research and Technology License Option Agreement with Mayo Clinic, Rochester, MN, for the development of a smallpox vaccine technology.

TapImmune Inc. (OTC BB: TPIV) announced that it has signed an exclusive Licensing Option agreement with Mayo Clinic, Rochester, MN, for clinical development of a breast cancer vaccine technology.

TapImmune Inc. (OTCBB: TPIV) announced today that the Company has completed the sale of Senior Secured Convertible Notes (“Notes”) totaling $1.53 million.

TapImmune Inc. (OTCBB: TPIV), a Nevada corporation, announced today that the Company entered into a definitive purchase agreement on May 17, 2010 with accredited investors to place Senior Secured C...

The FDA has approved Dendreon's Provenge, a breakthrough cancer vaccine that promises to extend the lives of prostate cancer victims by several months.

TapImmune Inc. (OTCBB: TPIV), is pleased to provide this corporate update to our shareholders and other interested parties.

TapImmune Inc. (OTCBB: TPIV) announced that it has signed a Letter of Intent (LOI) with Aeras Global TB Vaccine Foundation to enter into an R&D collaboration effort.

Taplmmune, Inc. (TPIV.OB) announced that it has retained Wolfe Axelrod Weinberger Associates LLC as its investor relations counsel to communicate its strategic goals and business opportunities in o...

Taplmmune, Inc. (TPIV.OB) announced today President Denis Corin will be presenting at the OneMedPlace’s Forum 2010, Emerging Company Finance Conference, on Wednesday, January 13, 2010, at 9:15 a.m....

TapImmune Inc. (OTCBB: TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases...

TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, has signed a license agreement with Crucell...

TapImmune Inc. (OTCBB: TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, provides this corporate update.

TapImmune Inc. (OTC.BB:TPIV - News), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announces the acquisition of thre...

TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announces the appointment of Dr. Glynn W...

TapImmune Inc., (OTCBB: TPIM) announced today the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent No. 7,378,087, entitled “Method of Enhancing an Immune Response.

TapImmune Inc. (OTC BB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced that the company has ex...

TapImmune Inc. (OTC BB:TPIM.OB - News), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced that an indepe...

TapImmune Inc. (OTC BB:TPIM.OB - News) (Frankfurt:GX1A.F - News) announces completion of initial testing on our bench made vaccine at AppTech.

TapImmune Inc., (OTCBB: TPIM; Germany: GX1A) announced today the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application No. 10/046,542, entitled “Meth...

VANCOUVER, BC - January 15, 2008 -- TapImmune Inc. (OTC BB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, tod...

VANCOUVER, Canada, – TapImmune Inc., (OTCBB: TPIM) (the “Company”) a biotechnology specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today annou...

,– TapImmune Inc., (OTCBB: TPIM; Germany: GX1A) a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced FDA co...

TapImmune Inc., (OTCBB: TPIM; Germany: GX1A) a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced a contrac...

VANCOUVER, Canada, 31 July, 2007 – TapImmune Inc., a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, opens new laborator...

VANCOUVER, British Columbia, July 17, 2007 (PRIME NEWSWIRE) -- TapImmune Inc., a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious d...

VANCOUVER, BC – TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced today that it ...